Brokerages forecast that G1 Therapeutics (NASDAQ:GTHX) will announce earnings of ($0.64) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for G1 Therapeutics’ earnings. The highest EPS estimate is ($0.62) and the lowest is ($0.66). The company is expected to issue its next quarterly earnings report on Wednesday, May 16th.
According to Zacks, analysts expect that G1 Therapeutics will report full-year earnings of ($2.47) per share for the current year, with EPS estimates ranging from ($2.55) to ($2.40). For the next year, analysts anticipate that the business will report earnings of ($2.84) per share, with EPS estimates ranging from ($3.05) to ($2.48). Zacks’ earnings per share averages are an average based on a survey of research analysts that cover G1 Therapeutics.
G1 Therapeutics (NASDAQ:GTHX) last posted its earnings results on Wednesday, February 21st. The company reported ($0.60) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.02).
GTHX has been the topic of several recent research reports. JPMorgan Chase lifted their price target on G1 Therapeutics to $30.00 in a research note on Monday, February 5th. BTIG Research initiated coverage on G1 Therapeutics in a research note on Tuesday, December 19th. They issued a “buy” rating and a $38.00 price target on the stock. Cowen reissued a “buy” rating on shares of G1 Therapeutics in a research note on Monday, March 5th. BidaskClub raised G1 Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Finally, Needham & Company LLC lifted their price target on G1 Therapeutics to $42.00 and gave the company a “buy” rating in a research note on Tuesday, March 13th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $38.20.
GTHX stock opened at $35.37 on Friday. G1 Therapeutics has a 1-year low of $12.04 and a 1-year high of $42.78. The stock has a market cap of $1,206.55 and a price-to-earnings ratio of -9.91.
In related news, VP Jennifer K. Moses sold 750 shares of G1 Therapeutics stock in a transaction dated Thursday, April 5th. The stock was sold at an average price of $37.47, for a total value of $28,102.50. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Rajesh Malik sold 3,776 shares of G1 Therapeutics stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $20.00, for a total value of $75,520.00. The disclosure for this sale can be found here. Insiders sold a total of 13,578 shares of company stock worth $371,642 in the last three months.
Large investors have recently added to or reduced their stakes in the stock. American International Group Inc. acquired a new stake in shares of G1 Therapeutics in the third quarter valued at about $130,000. California State Teachers Retirement System acquired a new stake in shares of G1 Therapeutics in the third quarter valued at about $319,000. Teachers Advisors LLC increased its position in shares of G1 Therapeutics by 44.6% in the fourth quarter. Teachers Advisors LLC now owns 13,818 shares of the company’s stock valued at $274,000 after acquiring an additional 4,260 shares during the last quarter. Swiss National Bank acquired a new stake in shares of G1 Therapeutics in the fourth quarter valued at about $286,000. Finally, Schwab Charles Investment Management Inc. acquired a new stake in shares of G1 Therapeutics in the third quarter valued at about $364,000. 42.78% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Brokerages Anticipate G1 Therapeutics (GTHX) Will Announce Earnings of -$0.64 Per Share” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/brokerages-anticipate-g1-therapeutics-gthx-will-announce-earnings-of-0-64-per-share.html.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Get a free copy of the Zacks research report on G1 Therapeutics (GTHX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.